OBIO — Orchestra BioMed Holdings Inc.
NASDAQ · Healthcare · Biotechnology
$4.92
+$0.02 (+0.41%)
Orchestra BioMed Holdings Inc. (OBIO) is a biotechnology company listed on NASDAQ. It is led by David P. Hochman, based in 150 Union Square Drive, New Hope, PA, United States, 18938, with about 86 employees. Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Latest reported OBIO revenue for 2025-09-30 was $861.0K. Net income was -$58.9M. Revenue was up 3.0% from 2025-06-30 to 2025-09-30. OBIO currently screens at market cap $231.7M.
Use this OBIO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OBIO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OBIO SEC filings page. Lician reads the product cache first so this HTML stays unique to Orchestra BioMed Holdings Inc. even when a live quote feed is slow.
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
OBIO Key Statistics
Market Cap
$231.74M
Volume
169,568
Previous Close
$5.44
Day Range
$5.35 – $5.50
P/B Ratio
5.63
EPS
-$1.66
Revenue
$2.64M
Net Income
-$61.02M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-4.4%
Profit Margin
-2313.3%
Employees
86
OBIO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $2.64M | $2.76M | $3.53M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$61.02M | -$49.12M | -$33.61M | -$378.75K |
| EPS (Diluted) | -$1.66 | -$1.48 | -$2.24 | -$0.02 |
Total Assets
$76.17M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$22.26M
Operating Cash Flow
-$50.56M
Free Cash Flow
$0.00
Orchestra BioMed Holdings Inc. Company Information
- Founder, Chairman of the Board of Directors & CEO
- David P. Hochman
- Headquarters
- 150 Union Square Drive, New Hope, PA, United States, 18938
- Website
- www.orchestrabiomed.com
- Phone
- 215 862 5797
- IPO / Founded
- 2020-08-04
- Sector
- Healthcare
- Industry
- Biotechnology